

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Mouse Anti-CD28 Monoclonal Antibody, Phycoerythrin Conjugated, Clone CD28.2

RRID:AB_396072

Type: Antibody

Proper Citation

BD Biosciences Cat# 555729, RRID:AB_396072

Antibody Information

URL: http://antibodyregistry.org/AB_396072

Proper Citation: BD Biosciences Cat# 555729, RRID:AB_396072

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Mouse Anti-CD28 Monoclonal Antibody, Phycoerythrin Conjugated, Clone CD28.2

Description: This monoclonal targets CD28

Target Organism: human

Clone ID: CD28.2

Antibody ID: AB_396072

Vendor: BD Biosciences

Catalog Number: 555729

Record Creation Time: 20250820T071803+0000

Record Last Update: 20250821T020219+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-CD28 Monoclonal Antibody, Phycoerythrin Conjugated, Clone CD28.2.

No alerts have been found for Mouse Anti-CD28 Monoclonal Antibody, Phycoerythrin Conjugated, Clone CD28.2.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Verhaegen M, et al. (2025) Sec61 translocon inhibitor flavitransin blocks selectively dengue virus polyprotein insertion in the ER with pan-orthoflavivirus antiviral potency. Cell reports, 44(12), 116642.

Liechti T, et al. (2023) A robust pipeline for high-content, high-throughput immunophenotyping reveals age- and genetics-dependent changes in blood leukocytes. Cell reports methods, 3(10), 100619.

Malouli D, et al. (2022) Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species. Cell host & microbe, 30(9), 1207.

Béziat V, et al. (2021) Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy. Cell, 184(14), 3812.

Berezhnoy A, et al. (2020) Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell reports. Medicine, 1(9), 100163.

Celis-Gutierrez J, et al. (2019) Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell reports, 27(11), 3315.